SIRIUS
Mepolizumab as Oral-Corticosteroid-Sparing Therapy
Doente / População Intervenção / Exposição Comparação Desfecho
In 135 patients with OCS-dependent severe eosinophilic asthma, mepolizumab 100 mg SC every 4 weeks reduced maintenance oral corticosteroid dose compared with placebo.
N
135
Desenho
RCT
Desfecho
OCS-dose reduction
Relevância
3
ResultadoMedian 50% reduction vs 0% (p=0.007); exacerbations -32%.
Bel EH, et al. N Engl J Med. 2014;371(13):1189-1197. 10.1056/NEJMoa1403291
Discussão e crítica
Made OCS sparing a key indication for anti-IL-5 biologics.